Saturday 17 October 2026
Export RDY’s income statement to Excel — free account
Dr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.
13.05
0.15
+1.16%
Follow RDY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
17.26 | 18.23 | 25.79 | 36.49 |
P/S ratio |
2.95 | 2.97 | 3.22 | 3.30 | |
P/FCF ratio |
52.91 | 40.59 | 53.62 | 81.66 | |
P/Operating CF |
68.88 | 99.07 | 77.38 | (1,135.05) | |
P/B ratio |
2.86 | 2.79 | 2.84 | 2.78 | |
Price to Tangible BV |
4.16 | 4.02 | 4.12 | 3.98 | |
EV/Sales |
2.92 | 2.93 | 3.19 | 3.27 | |
EV/EBITDA |
11.04 | 11.71 | 15.04 | 18.87 | |
EV/Operating CF |
17.11 | 16.07 | 18.81 | 26.40 | |
EV/FCF |
52.33 | 40.00 | 53.09 | 80.90 | |
Quick Ratio |
1.11 | 1.18 | 1.13 | 1.16 | |
Current Ratio |
1.85 | 1.88 | 1.80 | 1.90 | |
Net Debt/EBITDA |
(0.50) | (0.78) | (4.36) | (1.07) | |
Debt/Assets |
10.81% | 12.03% | 13.34% | 12.51% | |
Debt/Equity |
0.16 | 0.18 | 0.20 | 0.19 | |
Asset Turnover |
0.68 | 0.66 | 0.60 | 0.57 | |
Operating CF/Net income |
1.02 | 0.87 | (13.83) | (0.21) | |
Capex/Depreciation |
(1.96) | (1.34) | (1.72) | (0.23) | |
Interest Coverage |
19.31 | 15.08 | (2.99) | 2.93 | |
Research and Development Expense of Revenue |
7.04% | 7.05% | 7.22% | 7.15% | |
Selling, General and Administrative Expense of Revenue |
30.02% | 30.85% | 39.21% | 35.64% | |
Intangible Assets out of Total Assets |
0.21 | 0.20 | 0.20 | 0.20 | |
Share Based Compensation of Revenue |
0.10% | 0.10% | 0.00% | 0.12% | |
Graham Net Nets |
0.10 | 0.11 | 0.10 | 0.10 | |
Graham Number |
9.45 | 9.33 | 7.67 | 6.83 | |
Earnings Yield |
5.79% | 5.48% | 3.88% | 2.74% | |
Free Cash Flow Yield |
1.89% | 2.46% | 1.86% | 1.22% | |
Revenue per Share |
1.22 | 1.17 | 0.71 | 1.09 | |
Operating CF per Share |
0.20 | 0.14 | 0.18 | (0.01) | |
Capex per Share |
(0.13) | (0.09) | (0.11) | (0.02) | |
Free Cash Flow per Share |
0.07 | 0.05 | 0.07 | (0.03) | |
Cash per Share |
0.95 | 1.11 | 1.13 | 1.10 | |
Shareholders Equity per Share |
4.90 | 5.02 | 4.87 | 5.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.90 | 5.02 | 4.87 | 5.22 | |
Free Cash Flow |
61.00 | 43.00 | 58.00 | (23.00) | |
Working Capital |
1,448.00 | 1,550.00 | 1,432.00 | 1,501.00 | |
Capital Expenditures |
(108.00) | (75.00) | (91.00) | (13.00) | |
Net Current Asset Value |
1,121.00 | 1,229.00 | 1,098.00 | 1,171.00 | |
EV/EBIT |
13.96 | 15.10 | 21.18 | 29.99 | |
Capex to Sales |
0.11 | 0.08 | 0.15 | 0.02 | |
Price to Operating Income |
14.12 | 15.32 | 21.39 | 30.27 | |
| Other line items | |||||
Average Receivables |
1,054.50 | 1,113.50 | 1,068.50 | 1,086.00 | |
Average Payables |
440.00 | 437.50 | 386.50 | 416.50 | |
Average Inventory |
857.00 | 858.00 | 824.00 | 866.00 | |
Average Assets |
5,834.00 | 5,944.50 | 5,973.50 | 6,069.00 | |
Average Common Equity |
3,884.50 | 3,971.50 | 4,000.50 | 4,105.50 |
Columns are period end dates